3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research
CIR Certificate is Extended for a Four-Year Period Between 2020-2024
3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.
The CIR “Credit Impôt Recherche” or French Research Tax Credit is a corporate tax relief measure that allows French companies to declare innovative research costs and obtain a significant reduction on their tax bill.
This renewal allows 3P’s French customers the opportunity to receive an important percentage of their R&D costs in tax credits. Therefore, 3P Biopharmaceuticals continues to bring added-value to their French clients thanks to this opportunity to increase the quality, safety and efficacy of their biologic drugs.
3P Biopharmaceuticals already counts with a strong French client portfolio at different stages of their biologics development who have embraced this interesting incentive over the last years.
As 3P Biopharmaceuticals CEO Dámaso Molero explains: “It is wonderful news to renew CIR certificate for another four years to confirm 3P Biopharmaceuticals, once again, as a valuable and competitive CDMO partner for French biotech and pharma companies interested in developing biologics.”
3P Biopharmaceuticals once again demonstrates its capacity to carry out processes development and manufacturing of molecules developed within diverse therapeutic applications. At the same time, 3P Biopharmaceuticals consolidates a competitive position among the most esteemed CDMOs in Europe.